10-Q: Vaxart's Q2 2026: Funding Cuts, Delisting, and Clinical Trials

Vaxart, Inc. reported a net loss of $13.5 million for Q2 2026, with a significant reduction in government contract revenue and continued operational expenses, alongside its delisting from Nasdaq.

Summary

• Vaxart, Inc. reported a net loss of $13.5 million for the three months ended June 30, 2026, and a net loss of $8.3 million for the six months ended June 30, 2026.
• Total revenue for the three months ended June 30, 2026, was $27.2 million, a decrease of 32% compared to the prior year period, primarily due to a 39% decrease in revenue from government contracts.
• Research and development expenses decreased by 32% to $33.8 million for the three months ended June 30, 2026, compared to the same period in 2025.
• General and administrative expenses increased by 44% to $6.6 million for the three months ended June 30, 2026.
• The company's common stock was delisted from The Nasdaq Capital Market effective December 1, 2025, and is now quoted on the OTCQX.
• The company has cash, cash equivalents, and short-term investments of $64.0 million as of June 30, 2026, with management expecting cash runway into the second quarter of 2027.
• Modification No. 7 to the 2024 ATI-RRPV Contract reduced the total authorized funding to $344.8 million, a decrease of $115.9 million from the previous authorization.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant reductions in government contract funding, delisting from Nasdaq, and ongoing substantial net losses, despite some progress in clinical development.

Positives

• The company reported positive topline results from a Phase 1 clinical trial for its second-generation norovirus vaccine constructs.
• The company received $25.0 million upfront from Dynavax for a COVID-19 vaccine candidate license and collaboration agreement.
• The company's oral COVID-19 vaccine candidate showed no vaccine-related serious adverse events or sustained Grade 3 or higher adverse events in the sentinel cohort of its Phase 2b study.
• Interest income increased by 86% to $0.6 million for the three months ended June 30, 2026, due to higher investment balances and favorable interest rates.

Negatives

• The company reported a net loss of $13.5 million for the three months ended June 30, 2026.
• Revenue from government contracts decreased by 39% to $24.3 million for the three months ended June 30, 2026.
• The company's common stock was delisted from Nasdaq and is now trading on the OTCQX, impacting liquidity.
• The total authorized funding under the 2024 ATI-RRPV Contract was reduced by $115.9 million.
• The company's cash runway is expected to extend into Q2 2027, indicating a need for future capital raises.
• General and administrative expenses increased by 44% for the three months ended June 30, 2026.

Risks

• If HHS BARDA were to further reduce, eliminate, delay, or object to funding available under the 2024 ATI-RRPV Contract, it could significantly and negatively impact revenues and cash flows, potentially forcing suspension or termination of product candidate development.
• There is no assurance that Dynavax Technologies Corporation (a Sanofi company) will continue to perform its obligations under the 2025 License and Collaboration Agreement or that Dynavax will not exercise its right to terminate the agreement.
• Changes in the regulatory environment for vaccines could adversely impact product development and commercialization efforts, potentially leading to new or heightened requirements, slower review timelines, or altered recommendations for use.
• The delisting from Nasdaq and trading on the OTCQX market may limit liquidity and the ability to issue additional securities or obtain financing.
• The company may be unable to retain coverage by securities or industry analysts due to its common stock not trading on a national securities exchange.
• If the company is unable to raise additional capital in sufficient amounts or on acceptable terms, it may be required to delay, limit, reduce, or terminate product development or future commercialization efforts.

Future Outlook

Management expects to have enough cash runway into the second quarter of 2027. The company anticipates incurring significant research and development expenses to advance its vaccine candidates through clinical trials and potential commercialization, with a portion of these costs potentially borne by third parties through partnerships. Future capital requirements will depend on factors such as clinical trial costs, manufacturing capabilities, and the ability to secure additional funding.

Management Comments

• "Our cash, cash equivalents and investments are not sufficient to fund the Companys planned operations for at least the period of 12 months from the date the unaudited condensed consolidated financial statements are issued."
• "Based on managements current plan, the Company expects to have enough cash runway into the second quarter of 2027."
• "If we are unable to raise additional capital in sufficient amounts or on acceptable terms, managements plans include further reducing or delaying operating expenses."
• "These conditions raise substantial doubt about our ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements."

Industry Context

StockSavvy.ai notes that Vaxart's financial performance and operational focus remain heavily tied to government funding, particularly from HHS BARDA, for its COVID-19 vaccine development. The reduction in contract funding and the delisting from Nasdaq highlight the challenging funding environment for clinical-stage biotech companies, especially those reliant on government grants and facing development setbacks.

Comparison to Industry Standards

• Vaxart's R&D spending as a percentage of revenue is significantly high, typical for clinical-stage biotech companies, but the decrease in R&D spending in Q2 2026 compared to Q2 2025 suggests a potential slowdown or shift in development priorities.
• The company's net loss per share of $(0.06) for Q2 2026 is consistent with the industry trend of early-stage biotechs operating at a loss while investing heavily in pipeline development.
• The reliance on government contracts for a substantial portion of revenue is a common strategy in the biopharmaceutical sector, especially for companies developing vaccines for public health threats, but it also introduces significant funding risk if such contracts are altered or terminated.

Corporate Governance

Legal Proceedings

• The company was involved in securities class action lawsuits (Himmelberg v. Vaxart, Inc. et al. and Hovhannisyan v. Vaxart, Inc. et al.) which were settled for $12.0 million, with $2.0 million paid by the company and the remainder by insurers. A jury trial against Armistice Capital, LLC concluded with a verdict in favor of Armistice.
• A shareholder lawsuit (Chan v. Vaxart, Inc. et al.) was dismissed with prejudice following the jury verdict in the related class action.

Stakeholder Impact

• Shareholders may experience continued dilution if the company raises capital through equity offerings.
• The delisting from Nasdaq and trading on OTCQX may negatively impact the liquidity and marketability of common stock for shareholders.
• Government funding agencies (HHS BARDA) are key stakeholders, with potential changes in funding impacting the company's operations and development timelines.
• The cooperation agreement with a stockholder group may lead to changes in board composition and governance practices, potentially impacting shareholder representation.

Next Steps

• Advance the norovirus program to the next stage of clinical development in 2026, pending partnership or funding.
• Continue to collect participant data over a 12-month period post-vaccination for the COVID-19 Phase 2b study.
• Anticipate topline data from the complete COVID-19 Phase 2b study (sentinel and main cohorts) in the first half of 2027.
• Work with governments to create pandemic monovalent influenza vaccines for emergency use or stockpiling.
• Continue development of the preclinical tri-valent seasonal influenza vaccine candidate.
• Make a regulatory filing to proceed with clinical trials for an HPV vaccine candidate.
• Continue to monitor and manage cash runway, potentially reducing or delaying operating expenses if additional capital is not raised.

Key Dates

Recommendation

Vaxart's Q2 2026 results show continued net losses and a significant reduction in government contract funding, compounded by its delisting from Nasdaq. While there are positive developments in its norovirus vaccine program and a collaboration with Dynavax/Sanofi, the overall financial health and reliance on external funding, coupled with the reduced government contract, present considerable risks. The company's ability to secure future funding and advance its pipeline, particularly the COVID-19 vaccine candidate under a reduced BARDA contract, remains uncertain. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of financial stability and successful progression of key clinical programs.

Keywords

Vaxart, COVID-19 vaccine, Norovirus vaccine, oral vaccine, HHS BARDA, clinical trial, biotechnology, SEC filing